On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hot telehealth stock Hims & Hers Health (NYSE: HIMS) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high. Yet Hims & Hers is still up nearly ...

Hims & Hers Health (NYSE: HIMS) is a telehealth company that went public through a special purpose acquisition company in 2021. Through a subscription model, it helps provide patients with access ...

Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator skyrocketed more than 670% between ...

Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million ...